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Abstract
A KIF6 variant in man has been reported to be associated with adverse cardiovascular outcomes after myocardial infarction.
No clear biological or physiological data exist for Kif6. We sought to investigate the impact of a deleterious KIF6mutation on
cardiac function in mice. Kif6 mutant mice were generated and verified. Cardiac function was assessed by serial
echocardiography at baseline, after ageing and after exercise. Lipid levels were also measured. No discernable adverse lipid
or cardiac phenotype was detected in Kif6 mutant mice. These data suggest that dysfunction of Kif6 is linked to other more
complex biological/biochemical parameters or is unlikely to be of material consequence in cardiac function.
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Introduction
There has been considerable debate within the cardiovascular
community regarding the role of kinesin-like protein 6 (Kif6) in
coronary artery disease. Initial reports using a candidate gene
based approach in several atherosclerosis population cohorts
observed an increase risk of adverse coronary events in carriers of
the rs20455 C variant in the KIF6 gene which leads to
a Trp719Arg substitution in the Kif6 protein [1,2,3,4]. These
findings were controversial and refuted by a large GWAS meta-
analysis using 19 case-control studies [5] where cases were defined
either by a history of prior myocardial infarction and/or the
presence of coronary artery disease at angiography. Furthermore
no association between the kif6 variant and coronary events was
observed in the most recent large meta-analysis [6]. However,
evidence from interventional randomized controlled trials (RCTs)
with statins associated carriage of this genotype with a greater
clinical response to statin therapy [7,8,9,10]. As a clinical test
based on KIF6 genotype was already on the market, the utility and
clinical significance of this was in doubt [11,12]. More recently,
retrospective analyses from several large independent RCTs
[13,14,15,16,17] have not observed an increased risk of adverse
vascular events or an attenuated response to statin therapy
amongst Kif6 719Arg carriers. In an attempt to reconcile these
discrepant findings, Ference et al hypothesized that the rs20455 C
variant in the KIF6 gene may influence LDL levels. By performing
a regression meta-analysis involving almost 145,000 patients, they
reported that carriers demonstrated greater reductions in LDL,
when treated with statins and consequently greater reduction in
clinical events when compared to non-carriers [6].
Kif6 is a member of the Kinesin 9 superfamily but the precise
molecular function of Kif6 is not known. It is likely to play a role in
the cellular transport of proteins along microtubules [18,19] and
could plausibly be involved in cellular transport in the cardiovas-
cular system. Hitherto, all studies have focused on investigating
polymorphism in the KIF6 gene within the context of coronary
artery disease yet to our knowledge there has been no investigation
(experimental or clinical) into its function (if any) on heart
function. We hypothesised that if loss of Kif6 function was
associated with cardiovascular disease, then mice with a deleterious
mutation in the Kif6 motor domain may exhibit defects in cardiac
physiology.
Therefore, we identified mice with an N-ethyl-N-nitrosourea
(ENU) induced mutation in the Kif6 motor, and investigated the
structural and functional cardiac phenotypes by high frequency
transthoracic echocardiography.
Methods
Kif6 mutant mice were obtained from the RIKEN Bioresource
Centre (Japan, RBRC03194), backcrossed 5 generations to
C57BL/6 and classed as incipient congenics. The likelihood that
a phenotype would arise because of a confounding mutation in the
RIKEN library is statistically slim (p,0.002) [20].
RT-PCR and Western blot analysis of Kif6 expression was
performed according to standard methods [21]. A rabbit poly-
clonal antibody (Kif6 C165) was generated using a peptide
containing 20 C-terminal amino acids of human Kif6 as an
immunogen. Specificity of the antibody was demonstrated by
showing competition of the antisera with the immunizing peptide
in cells transfected with recombinant full length human Kif6 (data
not shown).
Lipid levels were assessed at 18 weeks of age. Cardiac function
was measured using serial echocardiography in mice (some were
exercised on running wheels) for periods of time up to 43 weeks.
The supplemental methods and data contain additional in-
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formation. All animal work was carried out in strict accordance
with UK Home Office regulations under project licence approval
40/3307. The experimental protocols were approved by the
University of Sheffield ethical review board. All echocardiography
was carried out under isoflurane anaesthesia and all efforts were
made to minimize suffering.
Results
Kif6 Expression in Mouse Tissues, Generation of the kif6
Mutation in Mice, Confirmation and Prediction of Effect
on the Motor Domain
Kif6 protein was detected in a variety of tissues including heart
and endothelial cells (Figure 1A and B). To generate a model of
KIF6 mutation in mice, exons 2, 3 and 7 were sequenced in
.7000 DNA samples from ENU-mutagenised mice in the
RIKEN Biorepository. This led to the identification of an A to
G mutation in the exon 3 splice acceptor site of the Rgsc2221
(RBRC03194) mouse line (Fig. 1C). Since this nucleotide change is
predicted to disrupt splicing of the KIF6 mRNA, we re-derived
these mice by microinjection of sperm from an F1 Rgsc2221 male
into C57BL/6 oocytes so as to permit experimental testing of the
possible role for Kif6 in cardiac dysfunction. Subsequently,
offspring carrying the mutation were identified by PCR and
HpyCH4V restriction digest, and maintained on the C57BL6/J
background.
We extracted RNA from KIF6 mutant and wild type littermates,
and conducted RT-PCR with forward and reverse primers located
Figure 1. Kif6 expression in tissues, cells, mutant mice and structural information. (A) Multi-tissue Western blot analysis of Kif6 protein
expression. 20 mg of total protein from each tissue was separated by PAGE. The predicted molecular weight of Kif6 is 92KDa. An arrowhead indicates
the Kif6 protein recognized by the C165 antisera. (B) Transfected c-myc epitope tagged Kif6a in HEK 293 cells and Kif6 in primary endothelial cells
(HUVEC). (C) DNA sequence of exon 3 in Kif6 mutants, showing the A.T mutation at the22 position of the exon 3 splice acceptor site. (D) RT-PCR of
Kif6 RNA extracted from heart and brain tissue of wild type and mutant mice. (E) cDNA sequence of the mutant RT-PCR product, showing exon 2
reading into exon 4. (F) Ribbon representation of mouse KIF6 motor domain modeled on the crystal structure of the human KIF9 motor domain in
complex with ADP (PDB 3nwn). The ADP molecule is represented in a sticks model and the region (residue K59 to residue S86) corresponding to exon
3 deletion is shown in red. Secondary structure elements are numbered according to the convention for the kinesin motors.
doi:10.1371/journal.pone.0054636.g001
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in exons 1 and 5 respectively, to investigate any differences in
splicing of the KIF6 mRNA (Fig. 1D). This revealed the
amplification of a shorter PCR product in heterozygous and
homozygous mutant mice, implying an alteration in splicing.
Sequencing of the shorter product revealed that the effect of the
mutation is to cause exon 3 to be skipped from the KIF6 mRNA
(Fig. 1E). This leads to a novel transcript encoding a shortened
Kif6 protein with a 25 amino acid in-frame deletion in the motor
domain. On this basis we propose the name KIF6DE3 for this allele.
Kif6 shares 38% identical amino acid sequence with human Kif9.
Kinesin motor domains all have rather similar structures,
consisting of eight b-sheet strands sandwiched between six a-
helices (three on either side, Fig. 1F). The core of the motor
domain is made up by strand b1 up to and including helix a6. The
major effect of exon 3 deletion from the KIF6 gene, is to generate
a product missing several elements of secondary structure
necessary to support the core of the protein (deletion of b1c-b2-
a1). In addition, the nucleotide-binding pocket lies in a groove
partially formed by helix a1, which is absent in the Kif6 mutant
protein. Helix a1 leads directly into the highly conserved N21
region (nucleotide binding region or P-loop), and contains
conserved residues across kinesins and myosins. The P-loop is
the highest conserved region across kinesin and myosin families,
therefore preceding structural elements such as helix a1, are
crucial to maintain the loop conformation necessary for motor
function even though they do not seem to bear any specific
function. It is therefore highly likely that the gene produced by
deletion of exon 3 has a misfolded motor domain, unable to bind
or hydrolyze ATP.
Lipid and Cardiac Phenotype of Kif6 Mutant Mice
Fasted lipid levels at 18 weeks of age indicated trends toward
higher triglyceride levels in mutant mice but this did not reach
statistical significance (Figure S1). Echocardiography at 6 weeks of
age revealed no significant differences in Left (LVIDd), right
(RVIDd) ventricle cavity size (Fig. 2a and b) or LV contractility
(Fig. 2c) and tissue Doppler velocities (Table S1). When
contractility was defined with M-Mode derived indices, KIF6DE3/
+ mice had mildly reduced LV fractional shortening and ejection
fractions compared to homozygous mice only (Table S1). Left
ventricle derived heart rate (Fig. 2d), stroke volume (ml) (Fig. 2e),
aortic VTI (cm) and cardiac output (Fig. 2f) were not significantly
different between groups (Table S1).
To evaluate cardiac function with increasing age, serial
echocardiographic studies in mice after a further 6 and 12 weeks
were performed (Table S1). No significant differences between the
three strains of mice in all of the twelve parameters studied were
found, except for a higher LVPWTDISa velocity in the KIF6DE3/+
mice at 18 weeks of age (Table S1). Echocardiography was also
performed in older mice at 43 weeks of age and we observed no
evidence of reduced cardiac function in KIF6DE3/DE3 homozygous
mice (Table S1).
Exercise Capacity and Cardiac Function in Adult Mice
To determine if a physiological stressor such as exercise could
lead to the development of an abnormal cardiac phenotype,
voluntary wheel running was assessed in female KIF6 DE3/DE3 mice
after an exercise period of 13 weeks.
Figure 2. Serial cardiac function in adult male Kif6 mutant mice. Serial assessment (6–18 weeks) revealed no significant difference at either
time point in size of A) Left or B) Right ventricle in diastole, C) LV contractility measured by fractional area change (FAC), D) heart rate, E) Stroke
volume or F) Cardiac output. N= 4 per group.
doi:10.1371/journal.pone.0054636.g002
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There were no significant differences in the distances (.5 Km/
night) run by the mice (data not shown) or the relevant ventricular
physiology parameters (Figure S2 and Table S2).
Discussion
This study is the first to undertake whole animal research with
mutant KIF6 mice, and the first to attempt to find a physiological
cardiac effect related to altered Kif6 function. Only one other
study has attempted to link KIF6 genotype with a vascular
biological process, namely endothelial progenitor cell (EPC)
production in humans. This study revealed that the Arg/Arg
KIF6 genotype was associated with a lower tendency to produce
late outgrowth EPCs [22]. This was suggested to be as a result of
Kif6 effects on cytokinesis.
Given the existing expression data detailing high Kif6 mRNA
expression in rodent cardiac muscle (http://www.ebi.ac.uk/gxa/
gene/ENSRNOG00000011453?ef = organism_part) which we
formally confirm in mouse heart in this study, we speculated that
Kif6 dysfunction might impact lipid profiles, cardiac structure and
function at rest or after exercise in mice, despite there being no
prior human association studies. Our data also clearly show that
there is no effect of disrupting the Kif6 motor domain on cardiac
structure or function even when mice are studied up to the age of
43 weeks or under exercise conditions. There was no significant
impact of the Kif6 mutation upon lipid levels; we assert therefore,
that it is unlikely that dysfunction of the Kif6 motor protein has
any discernable effect on cardiac function. Interestingly, and in
support of our work, Davani et al. [22] did not observe any
significant difference in LV ejection fraction after acute myocar-
dial infarction in relation to KIF6 genotype.
Study Limitations
In our study we investigated the effects of a mutation that lies
within the motor domain of the KIF6 gene, whereas the variant
studied in humans lies within the tail domain. However given that
the motor domain mutation under investigation here is likely to
lead a non-functional KIF6 gene, we believe nonetheless that it
remains a useful model to determine the role of kif6 in cardiac
function.
Our study primarily investigated whether mice with non-
functioning kif6 had impaired ventricular function. Although we
did not specifically investigate atherosclerosis, we observed no
significant differences in lipid levels in KIF6DE3/DE3 mice. Group
sizes were 8 animals and study power was 74% for these measures.
It is possible that much larger group sizes may have revealed
statistically significant differences. However, unlike humans, mice
have much lower LDL levels and given the reported link between
the kif6 variant with higher LDL levels and adverse coronary
events [6], it is possible that effects of Kif6 may only be revealed on
a proatherogenic mouse background (such as apoE or LDL-
receptor null mice fed a high fat diet).
Conclusion
The data presented here strongly suggest that mice with
a mutation within the motor domain of Kif6 (KIF6DE3) mutant
mice have no discernible adverse cardiac phenotype.
Supporting Information
Figure S1 Lipid levels in Kif6 mutant mice at 18 weeks of age.
No significant differences were obtained, n= 628 each group.
(TIF)
Figure S2 Exercise and cardiac function in adult female Kif6
mutant mice. After voluntary wheel running for 13 weeks, no
significant differences were observed between groups in A) Cavity
size (diastole), B) LV mass, C) Fractional shortening (%), D
Fractional area change (FAC), E) posterior wall systolic wave
velocity using tissue Doppler, F) cardiac output, n = 4.
(TIF)
Table S1 Detailed physiological and echocardiographic dataset
for adult male Kif6 mutant mice undergoing serial echocardiog-
raphy between 6–43 weeks of age. Data are presented as mean
[SEM].
(PDF)
Table S2 Detailed physiological and echocardiographic dataset
for adult female Kif6 mutant mice after continuous voluntary
wheel running for 13 weeks. Data are presented as mean [SEM].
(TIF)
Methods S1 Supplementary methods.
(DOCX)
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